Cephalothin

Summary

Cephalothin (CHEMBL617) is an approved small-molecule antimicrobial agent (ATC J01DB03) targeting SLC22A8 and SLC22A11; indicated across 1 condition including bacterial infectious disease.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: J01DB03
• Targets: 2 (SLC22A8, SLC22A11)
• Indications: 1 condition
• Chemistry: 396.4 Da · C16H16N2O6S2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL617
Name	Cephalothin
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	6024
ChEBI	CHEBI:124991
ATC	J01DB03
Molecular formula	C16H16N2O6S2
Molecular weight	396.4
InChIKey	XIURVHNZVLADCM-IUODEOHRSA-N

SMILES: CC(=O)OCC1=C(N2[C@@H]([C@@H](C2=O)NC(=O)CC3=CC=CS3)SC1)C(=O)O

IUPAC name: (6R,7R)-3-(acetyloxymethyl)-8-oxo-7-[(2-thiophen-2-ylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid

ChEBI definition: A semisynthetic, first-generation cephalosporin antibiotic with acetoxymethyl and (2-thienylacetyl)nitrilo moieties at positions 3 and 7, respectively, of the core structure. Administered parenterally during surgery and to treat a wide spectrum of blood infections.

Pharmacological roles (ChEBI): antimicrobial agent, antibacterial drug.

Also known as: Cefalotin, Cefalotina, Cefalotine, cephalothin, Cephalothin, Cephalotin, SID29215241, SID90341219, Cefalothin, SID47193756, CEFALOTINE, SID170465101

Parent form; salt/anhydrous children: CHEMBL1632

Patent coverage: 7,159 distinct patent families (24,927 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
SLC22A8	Organic anion transporter 3	Inhibition	7.59	0.3%	Q8TCC7
SLC22A11	Organic anion transporter 4	Inhibition	6.7	0.2%	Q9NSA0

Broader ChEMBL bioactivity targets: 13 (assay-derived). Sample: Tyrosyl-DNA phosphodiesterase 1, Microtubule-associated protein tau, Fructose-bisphosphate aldolase, 4’-phosphopantetheinyl transferase ffp, 15-hydroxyprostaglandin dehydrogenase [NAD(+)], Solute carrier family 22 member 6, Organic anion transporter 3, Carboxy-terminal domain RNA polymerase II polypeptide A small phosphatase 1, DNA (cytosine-5)-methyltransferase 1, Organic anion transporter 3.

Bioactivity

ChEMBL activities: 5 potent at pChembl ≥ 5 of 14 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
SLC22A8	7.4	Ki	40	nM	CHEMBL_ACT_11002249
SLC22A11	6.7	Ki	200	nM	CHEMBL_ACT_11002276
SLC22A6	6.66	Ki	220	nM	CHEMBL_ACT_11002268
CTDSP1	5.55	IC50	2786	nM	CHEMBL_ACT_6963814
DNMT1	5.14	IC50	7280	nM	CHEMBL_ACT_10221419

Target pathways

Aggregated over 2 target gene(s): SLC22A8, SLC22A11.

Top Reactome pathways

7 total, by targets touching each:

Pathway	Targets	Genes
Transport of small molecules	2	SLC22A11, SLC22A8
R-HSA-425366	2	SLC22A11, SLC22A8
SLC-mediated transmembrane transport	2	SLC22A11, SLC22A8
R-HSA-549132	2	SLC22A11, SLC22A8
Organic anion transport by SLC22 transporters	2	SLC22A11, SLC22A8
Drug ADME	1	SLC22A8
Ciprofloxacin ADME	1	SLC22A8

Dominant GO biological processes

GO term	Targets
monoatomic ion transport	2
obsolete organic anion transport	2
prostaglandin transport	2
inorganic anion transport	2
transmembrane transport	2
response to toxic substance	1
transport across blood-brain barrier	1
lipid transport	1
xenobiotic transport	1
urate metabolic process	1

Indications & clinical

Indications

1 indication (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
bacterial infectious disease	4	MONDO:0005113	EFO:0000771

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

58 molecules share ≥1 primary target. Top 58 by shared-target count:

Molecule	Source	Status	Shared targets
AMINOHIPPURIC ACID	ChEMBL + PubChem	Phase 4 (approved)	SLC22A11, SLC22A8
CEFAZOLIN	ChEMBL + PubChem	Phase 4 (approved)	SLC22A11, SLC22A8
CEFOTAXIME	ChEMBL + PubChem	Phase 4 (approved)	SLC22A11, SLC22A8
CEFTRIAXONE	ChEMBL + PubChem	Phase 4 (approved)	SLC22A11, SLC22A8
CIMETIDINE	ChEMBL + PubChem	Phase 4 (approved)	SLC22A11, SLC22A8
INDOMETHACIN	ChEMBL + PubChem	Phase 4 (approved)	SLC22A11, SLC22A8
PENICILLIN G	ChEMBL + PubChem	Phase 4 (approved)	SLC22A11, SLC22A8
PHENYLBUTAZONE	ChEMBL + PubChem	Phase 4 (approved)	SLC22A11, SLC22A8
PIROXICAM	ChEMBL + PubChem	Phase 4 (approved)	SLC22A11, SLC22A8
PRAVASTATIN	ChEMBL + PubChem	Phase 4 (approved)	SLC22A11, SLC22A8
PROBENECID	ChEMBL + PubChem	Phase 4 (approved)	SLC22A11, SLC22A8
CEFAMANDOLE	ChEMBL	Phase 4 (approved)	SLC22A11, SLC22A8
CEFOPERAZONE	ChEMBL	Phase 4 (approved)	SLC22A11, SLC22A8
CEPHALORIDINE	ChEMBL	Phase 4 (approved)	SLC22A11, SLC22A8
ROLOFYLLINE	ChEMBL	Phase 3	SLC22A11, SLC22A8
Bumetanide	PubChem	Approved	SLC22A11, SLC22A8
caprylic acid	PubChem	Approved	SLC22A11, SLC22A8
Diclofenac	PubChem	Approved	SLC22A11, SLC22A8
Dinoprost	PubChem	Approved	SLC22A11, SLC22A8
dinoprostone	PubChem	Approved	SLC22A11, SLC22A8
Furosemide	PubChem	Approved	SLC22A11, SLC22A8
Ketoprofen	PubChem	Approved	SLC22A11, SLC22A8
Linagliptin	PubChem	Approved	SLC22A11, SLC22A8
Methotrexate	PubChem	Approved	SLC22A11, SLC22A8
Salicylic Acid	PubChem	Approved	SLC22A11, SLC22A8
Zidovudine	PubChem	Approved	SLC22A11, SLC22A8
CEFADROXIL	ChEMBL + PubChem	Phase 4 (approved)	SLC22A8
LESINURAD	ChEMBL	Phase 4 (approved)	SLC22A11
PAMIPARIB	ChEMBL	Phase 3	SLC22A8
BETAMIPRON	ChEMBL	Phase 2	SLC22A8
OCTANOIC ACID	ChEMBL	Phase 2	SLC22A8
VERINURAD	ChEMBL	Phase 2	SLC22A11
ZONAMPANEL	ChEMBL	Phase 2	SLC22A8
Acyclovir	PubChem	Approved	SLC22A8
Adefovir	PubChem	Approved	SLC22A8
Ampicillin	PubChem	Approved	SLC22A8
Aztreonam	PubChem	Approved	SLC22A8
cefaclor	PubChem	Approved	SLC22A8
Cefoxitin	PubChem	Approved	SLC22A8
Ceftazidime	PubChem	Approved	SLC22A8
Ceftiofur	PubChem	Approved	SLC22A8
Cefuroxime	PubChem	Approved	SLC22A8
cephalexin	PubChem	Approved	SLC22A8
Cloxacillin	PubChem	Approved	SLC22A8
Dicloxacillin	PubChem	Approved	SLC22A8
Ertugliflozin	PubChem	Approved	SLC22A8
Estradiol	PubChem	Approved	SLC22A11
Famotidine	PubChem	Approved	SLC22A8
Ganciclovir	PubChem	Approved	SLC22A8
Nafcillin	PubChem	Approved	SLC22A8
Oxacillin	PubChem	Approved	SLC22A8
Penciclovir	PubChem	Approved	SLC22A8
Penicillin V	PubChem	Approved	SLC22A8
Quinidine	PubChem	Approved	SLC22A8
Tenofovir	PubChem	Approved	SLC22A8
Uric Acid	PubChem	Approved	SLC22A8
Valacyclovir	PubChem	Approved	SLC22A8
Valproic Acid	PubChem	Approved	SLC22A8